London · Pre-Seed–Series B · 14 people tracked
Also known as 4BIO PARTNERS LLP
Investment thesis
4BIO Capital is a specialist life sciences venture capital firm concentrating on advanced therapies. The firm targets companies developing treatments that address significant unmet medical and social needs, positioning its investments to deliver both scientific innovation and social impact.
Source: firm website, verified Aug 25, 2026.
Team · 14 people
from the firm's website
What they invest in
from 3 of 3 portfolio companiesBiotech ×3Healthtech ×2Deep Tech ×1Longevity ×1Medical Devices ×1
HQs:Japan×1United States×1
Investments · 3 tracked
founders shown can be your intro pathMarch Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission BiocapitalCancer FundFitz Gate VenturesModi VenturesPortal InnovationsTMC Venture Fund+1 more
Actithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue.
BiotechHealthtech
Darshan Dalal(Chief Medical Officer)
Co-investorsHadean VenturesM VenturesSofinnova PartnersBioqube Ventures
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsFast Track InitiativeRemiges Ventures, Inc.DCI Partners Co. Ltd.
Portfolio news
latest coverage across their companiesActithera · arcticstartup.com · Jul 10, 2025
Principals & officers · per Companies House
what is this? ⓘDirector · British · since 2024
Director · British · since 2024
Director · British · since 2024
Dmitry Kuzmin — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Andrey Kozlov — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Frequently asked questions
- What stage does 4BIO Capital invest at?
- 4BIO Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does 4BIO Capital focus on?
- 4BIO Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is 4BIO Capital located?
- 4BIO Capital is headquartered in London, GB.
Images
Co-investors · 12
Remiges Ventures is a venture capital firm focused on life sciences and drug discovery, backing biotech and therapeutics companies. It launched the RDiscovery Fund to incubate early-stage drug discovery projects.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
BGF provides minority growth capital and support to entrepreneurial small and medium-sized businesses across the UK and Ireland, from university spinouts to established brands.
Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
82VS is a venture studio embedded within Alloy Therapeutics, a discovery platform and service provider, collaborating with academics, entrepreneurs, pharma, and VCs across company creation, drug discovery, and development.
Takeda Ventures, Inc. is the corporate venture capital arm of Takeda, making venture-based investments in therapeutic and platform-based companies to build the pharmaceutical company's pipeline and create strategic growth opportunities.
Firms observed investing alongside 4BIO Capital, from public investor directories. Shared companies are the overlap with 4BIO Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.